

1. // 2008 . - 365 .
 2. , 2006. - - : « » - 2011. - 550 .
 528 .
 3. (.) . - : . - 2000. - 806 .
 4. // - 2006. - . 772-779.
 : « » - 2012. - 922 .
 5. . / [.] - - 2008 . - 37 .

6. (. , ,) .
 : « » - 2011. - 550 .
 7. - 3- . - 2006. - 482 . /
 8. / : . ' .
 9. , 2003. - 112 .
 10. (.) . : « » - 2002. - 624 .

24.04.2013

616-056.3-076-08-035:615.218.2

.
 :
 158
 18 50 .
 (IMMUNOCAP 100,
 Phadia).
 - 24 / .
 10-11 / .

 :
 158
 18 50 .

(ImmunoCAP 100, Phadia AB).

10-11 / . - 24 / . -

Krutsko A. S.

SIGNIFICANCE OF EOSINOPHILIC CATIONIC PROTEIN IN PATIENTS WITH CHRONIC PROSTATITIS

Key words: chronic prostatitis, eosinophilic cationic protein, allergen specific immunotherapy

158 patients with chronic prostatitis aged 18 to 50 years were examined. The level of eosinophilic cationic protein in the blood serum was measured by immuno fluoro ferment method (ImmunoCAP 100, Phadia AB). The averages of eosinophilic cationic protein in healthy people varied considerably with a median 10-11 ng / ml and a discriminant 24 ng / ml. The above values depended on sorts of test-systems. The eosinophilic cationic protein level depended on the severity and activity of inflammation in patients with chronic prostatitis and could be used for objective monitoring of the effectiveness of allergen specific immunotherapy.

: 615:322: 616.1/9

- 1 , " "
- 2 , " "
- 1 , " "
- 2 , " "
- 1 ,
- 2 ,

' () - , 10-50 % : - 17 % ,

- 18 %, - 13 %, - 29 %.
32,7 %

14- 1 1 %
(<^1 > ,

3 [4].

[1].

(1:10)

[2].

2 « 1- »
« » () 180611 1 / ,

[5], 0,1 [5];

[6], 50

3 [4]

3

9 / .

(28): 7

21- (0,2

1 %

2 [7]. 21-

1.

1,0 1 %

[7].

(1963) . . . 4

[7, 8].

» [3].

(1:10)

14
6, 12 18 / .

[9].

[4],
100, 200 300

1

1	2	3
- 1	- 1	- 2
- 1	- 1	- 1
- 1	- 1	- 1
- 1	- 1	- 1
- 1	- 1	- 1
- 1	- 1	- 1
		- 2

[10].

1, 50 %, 12 / 18 / - 6 %.

6 / - 39 %, 2: 6 12 / 18 / - 17 %.

3 3 (. 2) , 27 % 12 / 28 % 33% 6 / , 1 2 6

(= 6) 12 / , 3

	/ ,	, ,	, %
	—	3,00 (3-3)	—
1	18	2,83 (2-3)	6
	12	1,50 (1-2)*	50
	6	1,83 (1-2)*	39
2	18	2,50 (2-3)	17
	12	2,17 (1-3)*	28
	6	2,33 (2-3)*	22
3	18	2,17 (2-3)*	28
	12	2,20 (2-3)*	27
	6	2,00 (2-2)*	33

* - , < 0,05.

(. 3).

12 / , 3 6, 12 18 / , 2 23 %

1 2 6 - 8 %, 3 % 13 % 6, 12 18 / - 49 %, 14 %

	/ ,	/	, ,	, %
	—	3/12	3,25 (3-4)	—
- « »	1	0/6	2,83 (2-3)	13
	9	2/7	3,14 (2-4)	3
1	6	0/6	3,00 (3-3)	8
	12	1/6	3,17 (3-4)	3
	18	0/6	2,83 (2-3)	13
2	6	0/6	1,67 (0-3)*	49
	12	0/5	2,80 (2-3)	14
	18	0/6	2,50 (1-3)*	23
3	6	0/13	2,69 (2-3)*	17
	12	0/13	2,46 (1-3)*	24
	18	0/13	2,46 (0-3)*	24

* - , < 0,05.

3, 12 18 / 24 %, 6 / - 17 %.

13 %.

3 %.

[11].

1. « »

3 6, 12 18 / .

2. 3

3.

3,

1. *European Allergy White Paper / The UCB institute of Allergy.* - Meredith S editor. — Brussels. — 2001. — 57p.

2. : 15.00.01 / / — X., 2009. — 39 .

3. Shimonene G. / G. Shimonene, A. Laukjavichene // *Immunopathol., allergol., infectol.* — 2002. — Vol. 3. — P. 52-56.

4. // — 2001. — 528 .

5. 2001 / 2002 - / , 2001. - 1536 .

6. 61810 , 61 36/00, 61 36/533, 61 36/68. / — 201101416; 08.02.2011; . 25.07.2011, . 14.

7.

// — 1954. — . 26-48

8. // - 2002. 27 .

9. *Commission of the European Communities: Council Directive of 18 December 1986 on the Laws, regulating the Application of Principles of Good Laboratory Practice and the Verification of Their Applications for Tests on Chemical Substances (87/18/EEC). The Rules Governing Medicinal Products in the European Community.* — 1991. — Vol. 1. — P. 145-146.

10. / () / , 2000. - . 349-354.

11. 73556 , 61 35/00. / — 201203896; . 30.03.2012; . 25.09.2012, . 18/2012

31.01.2013

: 615: 22: 616.1/9_

« »

3

3

L. V. Yakovlieva, S. M. Marchyshyn, O. B. Lenitska,
S. S. Kozachok

**THE INVESTIGATION OF THE ANTIALLERGIC ACTIVITY
OF NEW ORIGINAL HERBAL COMPOSITIONS**

Key words: allergy, phytotherapy, herbal compositions, antiallergic activity.

The pharmacological screening of the antiallergic activity of new original herbal compositions on the model of "The ophthalmic response to the histamine administration" and the model of the lingering anaphylactic shock in guinea pigs has been conducted. The results showed antihistaminic and antiallergic activities of the investigated herbal collection 3. Therefore the future studies of this collection could be perspective. The herbal composition 3 consists of *Bidentis herba*, *Violae herba*, *Planginis majoris folium*, *Melissae folium*, *Urticae folium*, *Chamomillae flores*, *Agropyri rhizomata et radices*.

638,16/,17:615.324+615.322 638.16/.



• . . , . . . ”
. . . , . . .
. . . ,

• « » , .

' - « . . . » - , ,
(, - (- , -
, , , (- , ,)
, .) (-
; , .). , , - , ,
. 20 - [1].

003:2006 « . . . » 15.8-03079829-
» - « . . . » 24.4-03079829-004:2008, [2].

» ,
» ,
(- . . . ,
, , , , ; - 1,
2, , 6, , , , . ,
02568182/031671/01 02.09.2010.
- :
- - ;
- - [3];
- - ;
(